MAPK pathway activation selectively inhibits ASCL1-driven small cell lung cancer
Related Experiment Video
Updated: Oct 15, 2025

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Rebecca Caeser1, Christopher Hulton2, Emily Costa1,3
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Abstract:
Activation of mitogenic signaling pathways is a common oncogenic driver of many solid tumors including lung cancer. Although activating mutations in the mitogen-activated protein kinase (MAPK) pathway are prevalent in non-small cell lung cancers, MAPK pathway activity, counterintuitively, is relatively suppressed in the more aggressively proliferative small cell lung cancer (SCLC). Here, we elucidate the role of the MAPK pathway and how it interacts with other signaling pathways in SCLC. We find that the most common SCLC subtype, SCLC-A associated with high expression of ASCL1, is selectively sensitive to MAPK activation in vitro and in vivo through induction of cell-cycle arrest and senescence. We show strong upregulation of ERK negative feedback regulators and STAT signaling upon MAPK activation in SCLC-A lines. These findings provide insight into the complexity of signaling networks in SCLC and suggest subtype-specific mitogenic vulnerabilities.
Insights
Small cell lung cancer (SCLC), particularly the SCLC-A subtype, shows sensitivity to mitogen-activated protein kinase (MAPK) pathway activation. This activation induces cell-cycle arrest and senescence, revealing subtype-specific vulnerabilities.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Signaling
Background:
- Mitogenic signaling pathways drive many solid tumors, including lung cancer.
- While common in non-small cell lung cancer, MAPK pathway activity is paradoxically suppressed in small cell lung cancer (SCLC).
Purpose of the Study:
- To investigate the role and interactions of the MAPK pathway in SCLC.
- To identify subtype-specific vulnerabilities within SCLC signaling networks.
Main Methods:
- Analysis of MAPK pathway interactions in SCLC subtypes.
- In vitro and in vivo studies of MAPK activation in SCLC-A models.
Main Results:
- The ASCL1-high SCLC-A subtype is selectively sensitive to MAPK pathway activation.
- MAPK activation in SCLC-A induces cell-cycle arrest and senescence.
- MAPK activation upregulates ERK negative feedback regulators and STAT signaling in SCLC-A.
Conclusions:
- MAPK pathway activation presents a subtype-specific vulnerability in SCLC, particularly SCLC-A.
- Understanding these complex signaling networks is crucial for developing targeted SCLC therapies.
More Related Videos
11:32Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter
Published on: March 27, 2020
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Inhibition of Cdk Activity
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Intrinsic Apoptotic Pathway
Abnormal Proliferation